Non-small Cell Lung Cancer Clinical Trials in the EU, 2026
The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.
About this register
This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,637 trial records at the last sync on 16 Oct 2026, 03:17 UTC; this register shows the 2,557 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.
This page shows the 14 of those trials with a site in Non-small Cell Lung Cancer.
How many recently authorised EU trials have a site in Non-small Cell Lung Cancer?
14 of the 2,557 most recently authorised trials in this register list a site in Non-small Cell Lung Cancer; 4 of them are Phase III. Trials are counted by authorisation on CTIS, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.
Summary by phase
| Phase | Trials | Share |
|---|---|---|
| Phase II | 7 | 50% |
| Phase III | 4 | 28.6% |
| Phase I/II | 2 | 14.3% |
| Phase I | 1 | 7.1% |
Most active sponsors
| Lead sponsor | Trials |
|---|---|
| AstraZeneca AB | 2 |
| AbbVie Deutschland GmbH & Co. KG | 1 |
| Academisch Ziekenhuis Maastricht | 1 |
| AIO-Studien gGmbH | 1 |
| BioNTech SE | 1 |
| Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A. | 1 |
| Bristol-Myers Squibb Services Unlimited Company | 1 |
| Janssen Cilag International | 1 |
| Maia Biotechnology Inc. | 1 |
| Merus B.V. | 1 |